A population-based comparison of European and North American sinonasal cancer survival

A.A. Unsal, S. Kiliç, P.M. Dubal, S. Baredes, J.A. Eloy, EUROCARE-5 Working Group, Roberta De Angelis, Massimiliano Caldora, Silvia Giovanna Luisa Francisci, Sandra Mallone, Daniela Pierannunzio, Mariano Santaquilani, E. Carrani, Paolo Roazzi, Silvia Rossi, andrea tavilla

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: Sinonasal cancers (SNC) are rare, thus limiting previous prognostic studies on a multinational level. The aim of this study is to utilize two population-based datasets to compare prognoses for SNC between the United States (US) and Europe. Methods: The European Cancer Registry (EUROCARE) database and the United States National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database were searched to identify survival of patients diagnosed with SNC between 1990 and 2007. Relative survival (RS) data were stratified by age group, gender, geographic location, and diagnostic time period. Results: 12,541 SNC cases were identified in EUROCARE, while SEER identified 4,312. Males comprised the majority in Europe (62.3%) and the US (58.3%). Most patients were over 55 years in Europe (77.0%) and the US (69.5%). Age over 75 was a statistically significant poor prognostic indicator for 5-year RS in the US (48.2%; 95% CI = [43.9, 52.4]) and Europe (38.5%; [34.7, 42.7]). Female gender imparted a favorable 5-year RS in all regions except in Central Europe. By region, the US had the highest 5-year RS (58.8%; [56.4, 61.1]) and Eastern Europe had the lowest 5-year RS (37.1%; [34.0, 40.6]). The aggregate European 5-year RS was 48.1% [46.4, 49.8]. Conclusion: SNC in Europe and the US most commonly affects males and individuals over the age of 55 years. Male gender and age over 75 are poor prognostic factors at 5 years. Five-year RS in the US is higher than the 5-year European aggregate RS. © 2017 Elsevier B.V.
Original languageEnglish
JournalAuris Nasus Larynx
DOIs
Publication statusPublished - 2017

Fingerprint

Survival
Population
Neoplasms
Registries
Epidemiology
Databases
Eastern Europe
Geographic Locations
National Cancer Institute (U.S.)
Age Groups

Keywords

  • Europe
  • International
  • Population-based
  • Relative survival
  • SEER
  • Sinonasal cancer
  • Surveillance Epidemiology End Results
  • Survival
  • United States
  • adult
  • cancer prognosis
  • cancer registry
  • cancer survival
  • diagnosis
  • Eastern Europe
  • female
  • gender
  • human
  • male
  • national health organization
  • overall survival
  • prognosis

Cite this

@article{d3d33e6706f5467f83b36f10b752b421,
title = "A population-based comparison of European and North American sinonasal cancer survival",
abstract = "Objective: Sinonasal cancers (SNC) are rare, thus limiting previous prognostic studies on a multinational level. The aim of this study is to utilize two population-based datasets to compare prognoses for SNC between the United States (US) and Europe. Methods: The European Cancer Registry (EUROCARE) database and the United States National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database were searched to identify survival of patients diagnosed with SNC between 1990 and 2007. Relative survival (RS) data were stratified by age group, gender, geographic location, and diagnostic time period. Results: 12,541 SNC cases were identified in EUROCARE, while SEER identified 4,312. Males comprised the majority in Europe (62.3{\%}) and the US (58.3{\%}). Most patients were over 55 years in Europe (77.0{\%}) and the US (69.5{\%}). Age over 75 was a statistically significant poor prognostic indicator for 5-year RS in the US (48.2{\%}; 95{\%} CI = [43.9, 52.4]) and Europe (38.5{\%}; [34.7, 42.7]). Female gender imparted a favorable 5-year RS in all regions except in Central Europe. By region, the US had the highest 5-year RS (58.8{\%}; [56.4, 61.1]) and Eastern Europe had the lowest 5-year RS (37.1{\%}; [34.0, 40.6]). The aggregate European 5-year RS was 48.1{\%} [46.4, 49.8]. Conclusion: SNC in Europe and the US most commonly affects males and individuals over the age of 55 years. Male gender and age over 75 are poor prognostic factors at 5 years. Five-year RS in the US is higher than the 5-year European aggregate RS. {\circledC} 2017 Elsevier B.V.",
keywords = "Europe, International, Population-based, Relative survival, SEER, Sinonasal cancer, Surveillance Epidemiology End Results, Survival, United States, adult, cancer prognosis, cancer registry, cancer survival, diagnosis, Eastern Europe, female, gender, human, male, national health organization, overall survival, prognosis",
author = "A.A. Unsal and S. Kili{\cc} and P.M. Dubal and S. Baredes and J.A. Eloy and Group, {EUROCARE-5 Working} and {De Angelis}, Roberta and Massimiliano Caldora and Francisci, {Silvia Giovanna Luisa} and Sandra Mallone and Daniela Pierannunzio and Mariano Santaquilani and E. Carrani and Paolo Roazzi and Silvia Rossi and andrea tavilla",
note = "Export Date: 12 April 2018 Article in Press CODEN: ANLAD Correspondence Address: Eloy, J.A.email: jean.anderson.eloy@gmail.com",
year = "2017",
doi = "10.1016/j.anl.2017.09.009",
language = "English",
journal = "Auris Nasus Larynx",
issn = "0385-8146",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - A population-based comparison of European and North American sinonasal cancer survival

AU - Unsal, A.A.

AU - Kiliç, S.

AU - Dubal, P.M.

AU - Baredes, S.

AU - Eloy, J.A.

AU - Group, EUROCARE-5 Working

AU - De Angelis, Roberta

AU - Caldora, Massimiliano

AU - Francisci, Silvia Giovanna Luisa

AU - Mallone, Sandra

AU - Pierannunzio, Daniela

AU - Santaquilani, Mariano

AU - Carrani, E.

AU - Roazzi, Paolo

AU - Rossi, Silvia

AU - tavilla, andrea

N1 - Export Date: 12 April 2018 Article in Press CODEN: ANLAD Correspondence Address: Eloy, J.A.email: jean.anderson.eloy@gmail.com

PY - 2017

Y1 - 2017

N2 - Objective: Sinonasal cancers (SNC) are rare, thus limiting previous prognostic studies on a multinational level. The aim of this study is to utilize two population-based datasets to compare prognoses for SNC between the United States (US) and Europe. Methods: The European Cancer Registry (EUROCARE) database and the United States National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database were searched to identify survival of patients diagnosed with SNC between 1990 and 2007. Relative survival (RS) data were stratified by age group, gender, geographic location, and diagnostic time period. Results: 12,541 SNC cases were identified in EUROCARE, while SEER identified 4,312. Males comprised the majority in Europe (62.3%) and the US (58.3%). Most patients were over 55 years in Europe (77.0%) and the US (69.5%). Age over 75 was a statistically significant poor prognostic indicator for 5-year RS in the US (48.2%; 95% CI = [43.9, 52.4]) and Europe (38.5%; [34.7, 42.7]). Female gender imparted a favorable 5-year RS in all regions except in Central Europe. By region, the US had the highest 5-year RS (58.8%; [56.4, 61.1]) and Eastern Europe had the lowest 5-year RS (37.1%; [34.0, 40.6]). The aggregate European 5-year RS was 48.1% [46.4, 49.8]. Conclusion: SNC in Europe and the US most commonly affects males and individuals over the age of 55 years. Male gender and age over 75 are poor prognostic factors at 5 years. Five-year RS in the US is higher than the 5-year European aggregate RS. © 2017 Elsevier B.V.

AB - Objective: Sinonasal cancers (SNC) are rare, thus limiting previous prognostic studies on a multinational level. The aim of this study is to utilize two population-based datasets to compare prognoses for SNC between the United States (US) and Europe. Methods: The European Cancer Registry (EUROCARE) database and the United States National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database were searched to identify survival of patients diagnosed with SNC between 1990 and 2007. Relative survival (RS) data were stratified by age group, gender, geographic location, and diagnostic time period. Results: 12,541 SNC cases were identified in EUROCARE, while SEER identified 4,312. Males comprised the majority in Europe (62.3%) and the US (58.3%). Most patients were over 55 years in Europe (77.0%) and the US (69.5%). Age over 75 was a statistically significant poor prognostic indicator for 5-year RS in the US (48.2%; 95% CI = [43.9, 52.4]) and Europe (38.5%; [34.7, 42.7]). Female gender imparted a favorable 5-year RS in all regions except in Central Europe. By region, the US had the highest 5-year RS (58.8%; [56.4, 61.1]) and Eastern Europe had the lowest 5-year RS (37.1%; [34.0, 40.6]). The aggregate European 5-year RS was 48.1% [46.4, 49.8]. Conclusion: SNC in Europe and the US most commonly affects males and individuals over the age of 55 years. Male gender and age over 75 are poor prognostic factors at 5 years. Five-year RS in the US is higher than the 5-year European aggregate RS. © 2017 Elsevier B.V.

KW - Europe

KW - International

KW - Population-based

KW - Relative survival

KW - SEER

KW - Sinonasal cancer

KW - Surveillance Epidemiology End Results

KW - Survival

KW - United States

KW - adult

KW - cancer prognosis

KW - cancer registry

KW - cancer survival

KW - diagnosis

KW - Eastern Europe

KW - female

KW - gender

KW - human

KW - male

KW - national health organization

KW - overall survival

KW - prognosis

U2 - 10.1016/j.anl.2017.09.009

DO - 10.1016/j.anl.2017.09.009

M3 - Article

JO - Auris Nasus Larynx

JF - Auris Nasus Larynx

SN - 0385-8146

ER -